Results 251 to 260 of about 5,181,983 (378)

Short White Coats: Knowledge, Identity, and Status Negotiations of First‐Year Medical Students [PDF]

, 2018
Alexandra H. Vinson
openalex   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

"Are You Sick? No, I am Neurodivergent!" The Perilous Navigation Between Medicalization and Diagnostic Nihilism. [PDF]

Clin Neuropsychiatry
Troisi A.
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Factors Influencing the Choice Between Surgical Intervention and Physiotherapy for Individuals Experiencing Lumbar Spine Issues: A Qualitative Study in Iran. [PDF]

Patient Prefer Adherence
Amirshakeri B, Doshmangir L, Keyvani H.
europepmc   +1 more source

Foreword: Altruism, Community, and Markets [PDF]

, 2018
Krawiec, Kimberly D., Mahoney, Julia D., Satel, Sally L.   +2 more
core   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

"My Advice is to not let him in": How Support for Concerned Significant Others is Shaped by Professionals' Understandings of Alcohol and Other Drug Problems. [PDF]

Nordisk Alkohol Nark
Fagerström H, Lisa S, Ninive VG.
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Ethical issues in the use of genetic predictions of aggressive behavior in the criminal justice system: a systematic review. [PDF]

Front Genet
Refolo P, Ferracuti S, Grassi S, Raimondi C, Mercuri G, Zedda M, Aulino G, Spagnolo AG, Oliva A.   +8 more
europepmc   +1 more source